icon-folder.gif   Conference Reports for NATAP  
 
  HEPDART 2013: Frontiers in Drug Development for Viral Hepatitis
December 8-12, 2013
Big Island, Hawaii
Back grey_arrow_rt.gif
 
 
 
NS3/4A BASELINE POLYMORPHISMS AND TREATMENT-EMERGENT VARIANTS IN HCV GENOTYPE-1-INFECTED, TREATMENT-NAIVE PATIENTS FROM THE PHASE III STARTVerso 1 AND 2 CLINICAL STUDIES OF FALDAPREVIR PLUS PEGYLATED INTERFERON α-2A AND RIBAVIRIN
 
 
  Reported by Jules Levin
HEP DART 2013: December 8-12, Hawaii, USA.
 
AASLD: Boehringer Ingelheim - (11/18/13)
 
C Sarrazin1, KL Berger2, P Ferenci3, DM Jensen4, R Buynak5, J-F Dufour6, J-H Kao7, P Mantry8, LE Morano9, C Moreno10, SW Paik11, E Tam12, M Omata13, E Zehnter14, MS Sulkowski15, J Scherer2, JO Stern2, A-M Quinson2, and G Kukolj16 1J. W. Goethe University Hospital, Frankfurt, Germany; 2Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA; 3Medical University of Vienna, Vienna, Austria; 4University of Chicago Medicine, Chicago, IL, USA; 5Northwest Indiana Center for Clinical Research, Valparaiso, IN, USA; 6University Clinic for Visceral Surgery and Medicine, Bern, Switzerland; 7National Taiwan University Hospital, Taipei, Taiwan; 8The Liver Institute at Methodist Dallas Medical Center, Dallas, TX, USA; 9Hospital Meixoeiro, Vigo, Spain; 10H˘pital Universitaire Erasme, UniversitÚ Libre de Bruxelles, Brussels, Belgium; 11Samsung Medical Center, Sungkyunkwan University, Seoul, South Korea; 12LAIR Centre, Vancouver, BC, Canada; 13Yamanishi Central and Kita Hospitals, Yamanishi, Japan; 14Schwerpunktpraxis Hepatologie, Dortmund, Germany; 15John Hopkins University School of Medicine, Baltimore, MD, USA; 16Boehringer Ingelheim (Canada) Ltd, Burlington, ON, Canada

AASLD1.gif

AASLD2.gif

AASLD3.gif

AASLD4.gif

AASLD5.gif

AASLD6.gif

AASLD7.gif

AASLD8.gif

AASLD9.gif

AASLD10.gif

AASLD11.gif

AASLD12.gif

AASLD13.gif